肝硬化患者肝细胞癌筛查的经济负担
该多中心实用性随机临床试验于2018年3月至2021年4月纳入2872例肝硬化患者,对筛查结果阳性或不确定者及匹配的阴性者进行问卷调查,发现真阳性与假阳性患者的财务伤害增加,随访时21.8%患者报告中重度经济负担且与检测结果无显著关联,假阳性者财务伤害更重。
要点
- 真阳性与假阳性患者的财务伤害增加,真阴性与不确定者无显著变化。
- 随访时21.8%患者报告中重度经济负担,与检测结果无显著关联。
- 假阳性结果者的财务伤害频率与严重程度更高。
核心结论
- 肝细胞癌筛查的财务伤害因检测结果而异,可能构成障碍,在确定最佳筛查方案时必须加以考虑。
研究设计与样本
- 多中心实用性随机临床试验,2018年3月至2021年4月纳入2872例肝硬化患者进行肝细胞癌筛查外展。
- 至少完成1次随访调查的311例患者(应答率75%)中,真阳性37例、真阴性133例、假阳性64例、不确定77例。
- 采用癌症自填问卷测量财务伤害,采用慢性病治疗功能评估财务毒性综合评分测量经济负担,并进行单变量和多变量纵向回归分析。
- 按中心和检测结果抽样,对部分患者进行半结构化访谈。
主要发现
- 真阳性与假阳性患者的财务伤害增加,真阴性或不确定结果者无显著变化。
- 随访时21.8%的患者报告中重度经济负担,与检测结果无显著关联。
- 半结构化访谈显示财务伤害的频率和严重程度因检测结果而异,假阳性结果者伤害增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The overall value of hepatocellular carcinoma screening is defined by the balance of benefits and harms. Studies have only reported physical harms with none describing financial harms. METHODS: We conducted a multicenter pragmatic randomized clinical trial of hepatocellular carcinoma screening outreach among 2872 patients with cirrhosis from March 2018 to April 2021. Patients with positive or indeterminate results and matched patients with negative results completed surveys at baseline and at follow-up measuring financial harms via Cancer Self-Administered Questionnaire and financial burden via Comprehensive Score for Financial Toxicity Functional Assessment of Chronic Illness Therapy. Univariable and multivariable longitudinal regression analyses were performed to compare changes in financial harms across groups: true positive, true negative, false positive, and indeterminate. Semistructured interviews were conducted in a subset of patients, sampled by center and test result. RESULTS: Of 311 patients who completed at least 1 follow-up survey (75% response rate), 37 had true positive, 133 true negative, 64 false positive, and 77 indeterminate results. Financial harms increased in true positive and false positive patients with no significant changes noted among those with true negative or indeterminate results. At follow-up, 21.8% of patients reported moderate-severe financial burden, which was not significantly associated with test results. Semistructured interviews revealed variation in the frequency and severity of financial harms based on test results, with increased harm in those with false positive results. CONCLUSIONS: Financial harms of hepatocellular carcinoma screening vary by test result and can pose a barrier that must be considered when determining the optimal screening program.
引用
- Narasimman M, Hernaez R, Cerda V, et al. Financial Burden of Hepatocellular Carcinoma Screening in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023. PMID: 37544418. doi:10.1016/j.cgh.2023.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。